PRLD NASDAQ
Prelude Therapeutics Incorporated
1W: -5.4%
1M: -32.4%
3M: -26.4%
YTD: +34.4%
1Y: +143.1%
3Y: +19.5%
5Y: -89.4%
$3.67
-0.12 (-3.17%)
Weekly Expected Move ±9.4%
$3
$3
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (31)
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock Rated “Moderate Buy” by Sell-Side Analysts
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
BlackRock Inc. Acquires Shares of 1,797,501 Prelude Therapeutics Incorporated $PRLD
125,606 Shares in Prelude Therapeutics Incorporated $PRLD Acquired by Connor Clark & Lunn Investment Management Ltd.
Biotech Breakout: What's in focus after Moderna's cancer win?
Prelude Therapeutics (NASDAQ:PRLD) Sets New 1-Year High – Here’s What Happened
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
ADAR1 Capital Management LLC Makes New Investment in Prelude Therapeutics Incorporated $PRLD
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Prelude Therapeutics GAAP EPS of -$0.13 beats by $0.12, revenue of $4.58M
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
12 Health Care Stocks Moving In Thursday's After-Market Session
Seagate To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Monday
Prelude Therapeutics prices $90M equity offering
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
12 Health Care Stocks Moving In Thursday's Intraday Session
Prelude Therapeutics (NASDAQ:PRLD) Shares Up 4.3% – Still a Buy?
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics Earnings Report: Q4 Overview
Prelude Therapeutics GAAP EPS of -$1.29 misses by $0.04, revenue of $12.14M
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm